(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/066277 A1

(51) International Patent Classification:
A61K 31/18 (2006.01) *A61K 31/495* (2006.01)
A61K 31/445 (2006.01) *A61K 31/337* (2006.01)
A61K 31/40 (2006.01) *A61P 3/04* (2006.01)
A61K 31/397 (2006.01)

(21) International Application Number:
PCT/US2021/043434

(22) International Filing Date:
28 July 2021 (28.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17/030,902 24 September 2020 (24.09.2020) US

(71) Applicant: **GONGWIN BIOPHARM CO., LTD**; 3F, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW).

(71) Applicant *(for LC only)*: **WU, Lester, J.** [US/US]; Apt. 5F, 142-18 38th Avenue, Flushing, NY 11354 (US).

(72) Inventors: **WU, Shun-chi**; 3f, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW). **LIN, Mao-Yuan**; 3F, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW). **CHEN, Di-Rong**; 3F, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW). **YANG, Chuan-Ching**; 3F, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW). **ZHONG, Nan-Shan**; State Key Laboratory of Respiratory Disease, 29F, 151 Yanjiang Rd, Guangzhou, Guangdong, 510120 (CN). **TU, Chi-Chiang**; 3F, No. 80, Sec. 1, Jianguo N. Rd, ZhongShan Dist., Taipei City, 10449 (TW).

(74) Agent: **LU, Yu** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: METHOD FOR REDUCING FAT BY ADMINISTERING BENZENESULFONAMIDE COMPOSITIONS

(57) Abstract: Provided is a composition for reducing fat in the body of a subject, including a benzenesulfonamide derivative and a pharmaceutically or cosmetically acceptable carrier thereof. Also provided is a method for fat ablation or lipolysis by administering the composition to the subject in need thereof. Further provided is a method for preventing or treating a disease or condition related to fat accumulation by administering the composition to the subject in need thereof.

GWA101




FIG. 1A

WO 2022/066277 A1